ATHA — Athira Pharma Income Statement
0.000.00%
Last trade - 00:00- $93.52m
- -$53.90m
- 11
- 41
- 79
- 39
Annual income statement for Athira Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 5.45 | 19.8 | 64 | 104 | 125 |
| Operating Profit | -5.45 | -19.8 | -64 | -104 | -125 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.16 | -20 | -54.9 | -95.6 | -118 |
| Net Income After Taxes | -5.16 | -20 | -54.9 | -95.6 | -118 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.16 | -20 | -54.9 | -95.6 | -118 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.16 | -20 | -54.9 | -95.6 | -118 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.167 | -0.62 | -1.49 | -2.27 | -3.14 |
| Dividends per Share |